Plendil is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Plendil is a calcium channel blocker. It works by affecting the movement of calcium into the cells of the heart and blood vessels. Plendil relaxes blood vessels and increases the supply of blood and oxygen to the heart, which reduces the workload.
Plendil is available only with your doctor's prescription.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
PLENDIL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Plendil.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
PLENDIL may be administered with other antihypertensive agents.
How should I use Plendil?
Use Plendil as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Plendil should be regularly taken either without food or with a light meal
Avoid drinking grapefruit juice while taking Plendil
Do not to crush or chew tablets. Swallow them whole
If you miss a dose of Plendil, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once
Ask your health care provider any questions you may have about how to use Plendil.
Uses of Plendil in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
Hypertension: Management of hypertension
Off Label Uses
Chronic stable angina
Data from randomized, double-blind, placebo-controlled trials support the use of Plendil for the management of chronic stable angina, primarily in patients who continue to be symptomatic on an optimal dose of a beta-blocker.
Based on the 2012 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guideline for the diagnosis and management of patients with stable ischemic heart disease, a dihydropyridine calcium channel blocker (eg, Plendil) is an effective and recommended agent in the management of chronic stable angina. A beta-blocker is the preferred initial therapy for chronic stable angina; however, a dihydropyridine calcium channel blocker (eg, Plendil) may be added if there are ongoing anginal symptoms or may be used as alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade.
Plendil is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, Plendil prevents calcium-dependent myocyte contraction and vasoconstriction. Plendil is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, Plendil binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Plendil is used to treat mild to moderate essential hypertension.
Generic name: Plendil 2.5mg
Dosage form: tablet, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The recommended starting dose is 5 mg once a day. Depending on the patient's response, the dosage can be decreased to 2.5 mg or increased to 10 mg once a day. These adjustments should occur generally at intervals of not less than 2 weeks. The recommended dosage range is 2.5−10 mg once daily. In clinical trials, doses above 10 mg daily showed an increased blood pressure response but a large increase in the rate of peripheral edema and other vasodilatory adverse events. Modification of the recommended dosage is usually not required in patients with renal impairment.
PLENDIL should regularly be taken either without food or with a light meal. PLENDIL should be swallowed whole and not crushed or chewed.
Geriatric Use – Patients over 65 years of age are likely to develop higher plasma concentrations of Plendil. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range (2.5 mg daily). Elderly patients should have their blood pressure closely monitored during any dosage adjustment.
Patients with Impaired Liver Function – Patients with impaired liver function may have elevated plasma concentrations of Plendil and may respond to lower doses of PLENDIL; therefore, patients should have their blood pressure monitored closely during dosage adjustment of PLENDIL.
Plendil is metabolized by CYP3A4. Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with Plendil may lead to several-fold increases in the plasma levels of Plendil, either due to an increase in bioavailability or due to a decrease in metabolism. These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate). These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor). Caution should be used when CYP3A4 inhibitors are co-administered with Plendil. A conservative approach to dosing Plendil should be taken. The following specific interactions have been reported:
Co-administration of another extended release formulation of Plendil with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6-fold increase in the Cmax, and 2-fold prolongation in the half-life of Plendil.
Co-administration of Plendil with erythromycin resulted in approximately 2.5-fold increase in the AUC and Cmax, and about 2-fold prolongation in the half-life of Plendil.
Co-administration of Plendil with grapefruit juice resulted in more than 2fold increase in the AUC and Cmax, but no prolongation in the half-life of Plendil.
Co-administration of Plendil with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of Plendil.
A pharmacokinetic study of Plendil in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of Plendil. The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with Plendil and were well tolerated.
When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.
In a pharmacokinetic study, maximum plasma concentrations of Plendil were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the Plendil plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.
Plendil may increase the blood concentration of tacrolimus. When given concomitantly with Plendil, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.
Other Concomitant Therapy
In healthy subjects there were no clinically significant interactions when Plendil was given concomitantly with indomethacin or spironolactone.
Hypersensitivity to Plendil or to any of the excipients of Plendil-Natrapharm.
Plendil must not be taken by patients with any of the following conditions: Stroke within the last 6 months, cardiovascular shock, valvular heart disease (higher-grade aortic or mitral stenosis), heart muscle disease with narrowing of the cardiac cavity (hypertrophic obstructive cardiomyopathy), unstable angina pectoris, acute myocardial infarction (within the last 8 weeks), higher-grade disturbances of impulse conduction from the atria to the ventricles of the heart (2nd and 3rd degree AV block), congestive heart failure, severe impairment of liver and kidney function [renal insufficiency: glomerular filtration rate (GFR) <30 mL/min; creatinine >1.8 mg/dL], pregnancy.
Use in pregnancy: Plendil is contraindicated during the entire duration of pregnancy, as animal experiments have demonstrated fetal damage. Pregnancy must be excluded before starting treatment with Plendil.
Active ingredient matches for Plendil:
Felodipine in Argentina, Aruba, Australia, Bahamas, Bahrain, Barbados, Belgium, Bermuda, Canada, China, Costa Rica, Croatia (Hrvatska), Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, Estonia, Finland, Georgia, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, Indonesia, Iraq, Ireland, Italy, Jamaica, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Luxembourg, Malawi, Malaysia, Malta, Mexico, Mozambique, Netherlands, Netherlands Antilles, New Zealand, Nicaragua, Nigeria, Norway, Oman, Panama, Peru, Philippines, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sri Lanka, Sudan, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad & Tobago, Turkey, Uganda, United Arab Emirates, United Kingdom, United States, Vietnam, Yemen, Zambia, Zimbabwe.
DailyMed. "FELODIPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Plendil are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Plendil. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
There are no reviews yet. Be the first to write one!